HIV / AIDS

Daniel R. Kuritzkes, MD, describes how the unique mechanism of lenacapavir allows clinicians to maintain viral inhibition over time.

With major updates in HIV, C difficile, hepatitis, yeast infections, and skin and soft tissue infections, this week's Infectious Disease Update has something for everyone.

A germline-targeting HIV vaccine candidate elicited broadly neutralizing antibodies in 97% of recipients.

Read and watch the infectious disease trial data shared this week.

Concerns of injectable HIV PrEP safety and efficacy demonstrate a need for health care providers to share reliable information with at-risk populations.

Although HIV PrEP uptake is gradually increasing, usage remains low among key at-risk populations.

The study authors called eliminating barriers to HIV care and treatment a national priority.

Pregnant people taking dolutegravir were more likely to achieve HIV viral suppression and less likely to have a preterm birth than participants using other forms of ART.

With the population of adults with HIV growing older, incorporating age-based screenings, comprehensive assessments, and morbidity management into routine HIV care is essential in improving health outcomes and quality of life.

A late-breaking IDWeek 2022 study found high seroprotection was achieved among people living with HIV after receiving 3 doses of a hepatitis B vaccine.

A retrospective study of a Colombian cohort examined the causes of antiretroviral switch in people living with HIV/AIDS, as well as the time to ART switch.

The phase IIb trial evaluated whether adding a novel regimen of monthly azithromycin to a daily dose of trimethoprim-sulfamethoxazole would decrease the rate of STI at time of delivery among pregnant women living with HIV in Cameroon.

CRISPR edit of proviral DNA tested as potential cure for HIV in first participant of phase 1/2 clinical trial.

The intervention included meeting with experts, texting services to improve and facilitate communication, and data collection and dissemination.

Yasaswi Kislovskiy, MD, MSc, specialized in reproductive infectious disease to advocate for gender equity in health care.

Among pregnant women coinfected with HIV, a higher hepatitis C viral load increased the likelihood of transmitting HCV to children.

This will include 3 trials to examine the therapy in different formulations in HIV studies.

Gender-affirming hormone therapy (GAHT) therapy consists of administration of exogenous hormones and suppression of endogenous hormone production, with the goal of obtaining characteristics more congruent with an individual’s gender identity. Here is a review of these therapies and consideration for PrEP and the risks associated with HIV in this diverse population.

There are a number of programs designed to help lower rates of infection and transmission amongst this industry's workforce in South Africa.

Investigators noted 2 distinct phases of HIV virus levels, meaning any infected cells that survive treatment can become latent, only to reignite HIV infection after antiretroviral therapy is stopped.

Texas judge Reed O’Connor ruled that requiring employers to cover the medical expense of HIV PrEP is a violation of religious freedom.

Reviewers weigh evidence for the benefit of oral PrEP protection from HIV with risk of exacerbating hepatitis B.

Taking into account the first PrEP pill was FDA approved in 2012, a clinician reflects on its significance and where the shortcomings of education and utility of it needs to be fortified.

The European Commission approved lenacapavir to treat multidrug-resistant HIV infection. The long-acting HIV treatment regimen will be marketed as Sunlenca and available in injection or tablet form.